GCP
RIGL icon

GSA Capital Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

GSA Capital Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,927
Closed -$295K – 2111
2026
Q1 		$295K Buy
+10,927
New +$367K 0.02% 1261
2025
Q4 		– Sell
-41,771
Closed -$1.18M – 2020
2025
Q3 		$1.18M Buy
41,771
+850
+2% +$25.4K 0.1% 300
2025
Q2 		$766K Sell
40,921
-3,765
-8% -$71.4K 0.05% 632
2025
Q1 		$804K Buy
+44,686
New +$907K 0.07% 483
2024
Q3 		– Sell
-90,245
Closed -$742K – 1948
2024
Q2 		$742K Sell
90,245
-47,708
-35% -$499K 0.05% 716
2024
Q1 		$2.04M Sell
137,953
-4,751
-3% -$64K 0.16% 96
2023
Q4 		$2.07M Buy
142,704
+45,560
+47% +$466K 0.17% 107
2023
Q3 		$1.05M Buy
97,144
+61,281
+171% +$737K 0.09% 368
2023
Q2 		$463K Buy
35,863
+3,423
+11% +$46.3K 0.05% 791
2023
Q1 		$428K Buy
32,440
+22,913
+241% +$364K 0.04% 814
2022
Q4 		$143K Buy
+9,527
New +$87.3K 0.02% 1254
2021
Q4 		– Sell
-11,504
Closed -$418K – 1740
2021
Q3 		$418K Buy
+11,504
New +$453K 0.04% 806
2021
Q2 		– Sell
-1,604
Closed -$55K – 1557
2021
Q1 		$55K Buy
+1,604
New +$63.5K 0.01% 1027
2020
Q3 		– Sell
-8,443
Closed -$155K – 1366
2020
Q2 		$155K Sell
8,443
-14,112
-63% -$254K 0.09% 405
2020
Q1 		$352K Sell
22,555
-1,994
-8% -$42.4K 0.09% 381
2019
Q4 		$525K Buy
24,549
+4,436
+22% +$91.3K 0.06% 616
2019
Q3 		$376K Buy
+20,113
New +$416K 0.05% 735
2018
Q4 		– Sell
-2,790
Closed -$90K – 1679
2018
Q3 		$90K Buy
+2,790
New +$83.7K 0.01% 1567
2014
Q2 		– Sell
-1,328
Closed -$52K – 1937
2014
Q1 		$52K Buy
+1,328
New +$47.3K ﹤0.01% 1513

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GSA Capital Partners's RIGL Position: Q2 2026 in Review

GSA Capital Partners sold out of Rigel Pharmaceuticals (RIGL) in Q2 2026, closing a stake of 10,927 shares — an estimated $295K sold.

GSA Capital Partners first reported a position in RIGL in Q1 2014 and held it in 19 quarters. The position peaked at $2.07M in Q4 2023. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • GSA Capital Partners reported no remaining Rigel Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 10,927 Rigel Pharmaceuticals shares in Q2 2026, an estimated $295K.
  • GSA Capital Partners first reported a position in Rigel Pharmaceuticals in Q1 2014 and held it in 19 quarters.
  • GSA Capital Partners's Rigel Pharmaceuticals position peaked at $2.07M in Q4 2023.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.